Anixa Biosciences Announces Treatment of Second Patient in Ovarian Cancer CAR-T Clinical Trial

San Jose, California, May 22, 2023 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on cancer treatment and prevention, today announced in collaboration with partner Moffitt Cancer Center, its second patient of 2018. announced that he had started treatment. A clinical trial of a new chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer is underway.

This study (NCT05316129) is a Phase 1, dose escalation study to assess safety, determine the maximum tolerated dose of follicle-stimulating hormone receptor T cells, and evaluate preliminary clinical activity. The study is being conducted at Moffitt Cancer Center. All patients enrolled in the trial have ongoing disease and have failed at least two and possibly more therapeutic interventions. This patient will receive the same dose of engineered T cells as the first patient in the trial, and the next (third) patient will receive the same dose of genetically engineered T cells. Her three consecutive patient cohorts are expected to receive higher doses of cells.

The CAR-T approach used to treat Anixa is known as chimeric endocrine receptor T cells (CER-T) because the target of the engineered T cells is endocrine receptors. CAR-T therapy has shown efficacy in some hematologic malignancies, but replicating the same results in solid tumors such as ovarian cancer has proven difficult. One reason for this difficulty is that effective CAR-T therapy must recognize specific antigens present only on targeted cancer cells to avoid adversely affecting healthy cells. . The cell therapy being evaluated in Anixa’s Phase 1 study differs from conventional CAR-T in that it targets the follicle-stimulating hormone receptor (FSHR), which is only expressed in ovarian cells of healthy adult women Studies show that it does.

“We are optimistic about the potential for this treatment to impact ovarian cancer patients who have no other options. It’s about increasing enrollment at a rate,” he said. Robert WenhamMoffitt Cancer Center’s principal investigator for this trial.

“We are pleased to have treated a second patient in our ovarian cancer CAR-T clinical study,” he said. Amit Kumar, Chairman and CEO of Anixa Biosciences. “We anticipate an increase in patient recruitment rates and expect the third and possibly final patient in the current dose cohort to be treated in the near future. This is the early stages of patient enrollment. Therefore, we plan to announce the treatment of the second patient.” However, it is not our intention to announce the enrolment of each subsequent patient. Announcements will be made periodically as necessary. ”

About Anixa’s CER-T approach (follicle-stimulating hormone receptor-mediated CAR-T technology)
Anixa’s chimeric antigen receptor T cell (CAR-T) technology approach is an autologous cell therapy consisting of engineered T cells that target the follicle-stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels only on ovarian granulosa cells. Because the target is a hormone (chimeric endocrine receptor) receptor and the target binding domain is derived from its natural ligand, this technology is known as a new type of CAR-T, CER-T (chimeric endocrine receptor T cell) therapy. I’m here. .

About Anixa Biosciences
Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention. Anixa’s therapeutic portfolio consists of an ovarian cancer immunotherapy program under development in collaboration with Moffitt Cancer Center, a new type of his CAR- I am using T. The Company’s vaccine portfolio includes vaccines to prevent ovarian cancer, as well as novel vaccines in development with the Cleveland Clinic to prevent breast cancer, particularly triple-negative breast cancer (TNBC), the most fatal form of breast cancer. ing. These vaccine technologies focus on immunizing against ‘retired’ proteins found to be expressed in certain forms of cancer. Anixa’s unique business model of partnering with world-renowned research institutes in clinical development allows it to continuously explore emerging technologies in complementary areas for further development and commercialization. For more information, visit or follow Anixa. twitterLinkedIn, Facebook, YouTube.

Forward-Looking Statements: Statements that are not historical facts may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact but reflect Anixa’s current expectations regarding future events or results. We generally “believe,” “expect,” “intend,” “plan,” “anticipate,” “likely,” or “will” to identify forward-looking statements. ” and similar expressions. Such forward-looking statements, including statements about our expectations, involve risks, uncertainties and other factors, some of which are beyond our control and our actual Results, performance, achievements or industry results could differ materially from future results. any results, performance or achievements expressed or implied by such forward-looking statements; These risks, uncertainties and factors include those described in “Item 1A – Risk Factors” and other sections of our most recent annual report on Form 10-K and quarterly report on Form 10. include, but are not limited to: -Q and current report of Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should not place undue reliance on such forward-looking statements when evaluating the information contained in this press release.

Mike Caterani
[email protected]

Source Anixa Biosciences, Inc.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *